In Brief: Cytyc/Digene
This article was originally published in The Gray Sheet
Cytyc/Digene: Firms plan to collaborate on a 385-patient, single-center study -- set to begin in coming weeks -- to assess combined use of Cytyc's ThinPrep 2000 automated cervical sample preparation system and Digene's Hybrid Capture assay to screen for human papilloma virus. The study is expected to take less than three months and will support separate premarket approval application supplements, which could be submitted to FDA by year-end, according to Cytyc. Using the two systems in tandem, clinicians would be able to employ a single cervical specimen preserved in Cytyc's Preservcyt solution both for standard microscopic evaluation and for use on the Hybrid Capture if the initial screen is inconclusive. The combined usage would eliminate the need to call patients back to take a second sample if the first screen is inconclusive and follow-up testing for HPV is required, Cytyc says...
You may also be interested in...
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.